AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Revlimid - Drug Insight, 2019 - ResearchAndMarkets.com

March 12, 2019

DUBLIN--(BUSINESS WIRE)--Mar 12, 2019--The “Revlimid - Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering.

Revlimid Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.

Scope

  • A review of the Revlimid, based on information derived from company and industry-specific sources
  • Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
  • Coverage of the Drug Master Files and API Manufacturers by country
  • Patent Expiry Timeline and Exclusivity Details
  • Route of Synthesis of the API
  • Forecasted Sales Figure from 2019-2021
  • Market competition and emerging therapies
  • SWOT Analysis

Topics Covered

1. Report Introduction

2. Revlimid - Overview

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Regulatory Milestones by Region
  • Deals and Partnerships

3. Product Details

4. Revlimid Sales Assessment

  • Historical Sales
  • Forecasted Sales

5. Patent Details

6. Global API Manufacturers Assessment

  • Active Pharmaceutical Ingredient (API) Manufacturers by Country
  • Active Pharmaceutical Ingredient (API) Manufacturers by Region

7. Market Competition

8. Emerging Therapies

8.1 Drug 1: Company 1

  • Product Description
  • Research and Development
  • Product Development Activities

9. SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/research/8hqv8j/revlimid_drug?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190312005440/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/12/2019 07:05 AM/DISC: 03/12/2019 07:05 AM

http://www.businesswire.com/news/home/20190312005440/en